Gilead Sciences Inc. closed $7.05 short of its 52-week high ($98.90), which the company reached on November 11th.

Kyverna Therapeutics, Inc. (Kyverna), a clinical-stage biopharmaceutical company focused on developing cell therapies for ...

SAN ANTONIO -- Endocrine therapy after breast-conserving surgery was associated with worse health-related quality of life ...

Vir Biotechnology's phase 3 hepatitis programs and cancer trials are on the horizon. Read why VIR stock could benefit from ...

Gilead Sciences (NASDAQ:GILD) has received a positive recommendation for approval from European regulators for its drug ...

Sciences announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive ...

Berger specialized in cancer long before joining Genentech, holding oncology global clinical development roles at Amgen and ...

New research from Karolinska Institutet in Sweden highlights the possibility of screening people with type 2 diabetes for liver damage at the same time as they undergo screening for eye disease. The ...

In a report released today, Asthika Goonewardene from Truist Financial assigned a Hold rating to Gilead Sciences (GILD – Research Report). The company’s shares closed yesterday at $92.38. Pick the ...

Equities research analysts at Zacks Research raised their FY2025 earnings per share (EPS) estimates for Gilead Sciences in a ...

Gilead Sciences said on Thursday it has appointed Sanofi's Dietmar Berger as its chief medical officer, replacing incumbent ...